| Gene Name | NBAS |
| HF Protein Name | Neuroblastoma-amplified sequence |
| HF Function | Proviral host factor |
| Uniprot ID | A2RRP1 |
| Protein Sequence | View Fasta Sequence |
| NCBI Gene ID | 51594 |
| Host Factor (HF) Name in Paper | NAG |
| Gene synonyms | NAG |
| Ensemble Gene ID | ENSG00000151779 |
| Ensemble Transcript | ENST00000281513 [A2RRP1-1] |
| KEGG ID | Go to KEGG Database |
| Gene Ontology ID(s) | GO:0000149, GO:0000956, GO:0005783, GO:0005789, GO:0005829, GO:0006890, GO:0015031, GO:0016020, GO:0070939, GO:2000623, |
| MINT ID | N.A. |
| STRING | Click to see interaction map |
| GWAS Analysis | Click to see gwas analysis |
| OMIM ID | 608025 |
| PANTHER ID | N.A. |
| PDB ID(s) | N.A., |
| pfam ID | PF15492, PF08314, |
| Drug Bank ID | N.A., |
| ChEMBL ID | N.A. |
| Organism | Homo sapiens (Human) |
| Virus Name | Chikungunya virus |
| Virus Short Name | CHIKV |
| Order | Unassigned |
| Virus Family | Togaviridae |
| Virus Subfamily | N.A. |
| Genus | Alphavirus |
| Species | Chikungunya virus |
| Host | Human, mammals,mosquitoes and birds |
| Cell Tropism | N.A. |
| Associated Disease | Fever and joint pain |
| Mode of Transmission | By infected mosquito |
| VIPR DB link | https://www.viprbrc.org/brc/vipr_allSpecies_search.spg?method=SubmitForm&decorator=toga |
| ICTV DB link | https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/275/togaviridae |
| Virus Host DB link | N.A. |
| Paper Title | A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs |
| Author's Name | Alexander Karlas, Stefano Berre, Therese Couderc, Margus Varjak, Peter Braun Michael Meyer, Nicolas Gangneux, Liis Karo-Astover, Friderike Weege, Martin Raftery, Gu ?nther Scho ?nrich, Uwe Klemm, Anne Wurzlbauer, Franz Bracher, Andres Merits, Thomas F. Meyer & Marc Lecuit |
| Journal Name | nature communications |
| Pubmed ID | 27177310 |
| Abstract | Chikungunya virus (CHIKV) is a globally spreading alphavirus against which there is no commercially available vaccine or therapy. Here we use a genome-wide siRNA screen to identify 156 proviral and 41 antiviral host factors affecting CHIKV replication. We analyse the cellular pathways in which human proviral genes are involved and identify druggable targets. Twenty-one small-molecule inhibitors, some of which are FDA approved, targeting six proviral factors or pathways, have high antiviral activity in vitro, with low toxicity. Three identified inhibitors have prophylactic antiviral effects in mouse models of chikungunya infection. Two of them, the calmodulin inhibitor pimozide and the fatty acid synthesis inhibitor TOFA, have a therapeutic effect in vivo when combined. These results demonstrate the value of loss-of-function screening and pathway analysis for the rational identification of small molecules with therapeutic potential and pave the way for the development of new, host-directed, antiviral agents. |
| Used Model | A549 and HEK-293T cells |
| DOI | 10.1038/ncomms11320 |
